Tom Kraus, MHS, JD
The sweeping tariffs on all U.S. trading partners announced by the Trump administration on April 5 are likely to have a significant impact on the country’s pharmaceutical supply chain, particularly in the generic space, and could exacerbate existing drug shortages, experts say.
The order imposes a 10% tariff on all countries, as well as individualized reciprocal higher tariffs on the countries “with which the United States has the largest trade